Precision NanoSystems to Present at the 39th Annual Meeting & Exposition of the Controlled Release Society, July 15-18, 2012

Press Release

July 20, 2012

Precision NanoSystems, a provider of innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research, has been selected to present as part of the Soapbox Sessions at the Controlled Release Society (CRS) 39th Annual Meeting & Exposition that will take place at the Centre des congress de Québec, Québec City, Canada from the 15-18 July, 2012.

The CRS Soapbox Sessions introduce the latest, most novel technologies, products and services for delivery science. Euan Ramsay, COO, Precision NanoSystems will describe the NanoAssemblr manufacturing platform for the production of next-generation lipid nanoparticles during Session III on Sunday, July 15, 2012 from 2.30 PM – 3:10 PM.

About Precision NanoSystems, Inc.

At Precision NanoSystems we are creating innovative tools for the development and manufacture of best-in-class nanoparticles for use as medicines, and in medical research. Our proprietary NanoAssemblr platform enables the simple, rapid, reproducible, and scalable manufacture of next-generation nanoparticle formulations for the targeted delivery of therapeutic and diagnostic agents to difficult-to-access cells and tissues in the body. We provide instruments, reagents and services to life sciences researchers and build strategic collaborations to revolutionize healthcare through nanotechnology. To join the revolution visit our website.


IN THE NEWS

Press Release

The NanoAssemblr Blaze moves nanomedicine development from the preliminary stages of formulation screening and iteration onto large batch manufacturing of nanoparticles suitable for toxicology screening and analysis. Based on the proven N...

Read More


Press Release

Global leader in non-viral delivery of genomic medicines, Precision NanoSystems (PNI), entered into a strategic collaboration agreement with Aurora Vaccines to accelerate the development and manufacture of its Hepatitis C vaccine candidate. PNI will share its expertise in the dev...
Read More